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Abstract
Parkinson’s disease (PD)-mimicking drugs and pesticides, and more recently PD-associated gene mutations, have been
studied in cell cultures and mammalian models to decipher the molecular basis of PD. Thus far, a dozen of genes have been
identified that are responsible for inherited PD. However they only account for about 8% of PD cases, most of the cases
likely involving environmental contributions. Environmental manganese (Mn) exposure represents an established risk factor
for PD occurrence, and both PD and Mn-intoxicated patients display a characteristic extrapyramidal syndrome primarily
involving dopaminergic (DAergic) neurodegeneration with shared common molecular mechanisms. To better understand
the specificity of DAergic neurodegeneration, we studied Mn toxicity in vivo in Caenorhabditis elegans. Combining genetics
and biochemical assays, we established that extracellular, and not intracellular, dopamine (DA) is responsible for Mn-
induced DAergic neurodegeneration and that this process (1) requires functional DA-reuptake transporter (DAT-1) and (2) is
associated with oxidative stress and lifespan reduction. Overexpression of the anti-oxidant transcription factor, SKN-1,
affords protection against Mn toxicity, while the DA-dependency of Mn toxicity requires the NADPH dual-oxidase BLI-3.
These results suggest that in vivo BLI-3 activity promotes the conversion of extracellular DA into toxic reactive species,
which, in turn, can be taken up by DAT-1 in DAergic neurons, thus leading to oxidative stress and cell degeneration.
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Introduction
Mn is the twelfth most prevalent natural element in the Earth’s
crust [1] and is an essential transition metal required for normal
growth, development and cellular homeostasis [2,3]. It acts as a
cofactor for multiple enzymes (Mn superoxide dismutase, pyruvate
carboxylase, arginase, and glutamine synthase) [4,5,6,7,8] and can
substitute for magnesium (Mg) in many enzymatic reactions
catalyzed by kinases. Although dietary Mn intake by the
gastrointestinal tract (GIT) and excretion via the bile are tightly
regulated [9], inhalation of toxic concentrations of Mn can lead to
nasal and pulmonary inflammation, renal dysfunction and
neurodegeneration [7,10,11,12]. A recent study also suggests that
high levels of Mn in drinking water (.300 mg/liter) are associated
with reduced intellectual function in children [13]. Mn mining, steel
manufacturing and welding represent occupational exposures
linked to increased risk for parkinsonian syndrome [14,15]. In
addition, Mn is used in other industrial and agricultural
applications. Fungicides, such as Maneb or Mancozeb, increase
the risk of environmental Mn exposure in agricultural workers [16].
An organic Mn compound, methylcyclopentadienyl Mn tricarbonyl
(MMT), used as an octane booster or anti-knock agent in gasoline,
has also been shown to cause adverse health effects [17,18,19,20].
Exposure to high levels of Mn in occupational or environmental
settings or disease conditions (hepatic encephalopathy) [21] is
accompanied by Mn accumulation in specific brain regions that
are highlysensitive to oxidativeinjury, namely the substantia nigra (SN),
globus pallidus (GP) and striatum [22]. Excessive Mn deposition in these
regions leads to dopaminergic (DAergic) neuronal loss accompanied
by an extrapyramidal syndrome referred to as manganism.
Manganism patients exhibit rigidity, tremor, dystonic movements
and bradykinesia, all of which are also characteristic features of
Parkinson’sdisease(PD)[23,24,25].ExposuretoMnalsorepresentsa
risk factor for PD [26,27,28]. Indeed, the strongest correlation
between any type of environmental exposure and PD is noted in Mn-
exposed human cohorts [29], and occupational exposure to Mn for
.20 years or combined long-term exposures to Mn and Al (.30
years) are associated with an increased occurrence of PD [30].
Parkinsonism in welders (vs. non-welders) is clinically distinguishable
only by age of onset (46 vs. 63 years, respectively) [28], and the
prevalence of PD is higher among welders as compared with age-
standardized individuals in the general population [31].
PLoS Genetics | www.plosgenetics.org 1 August 2010 | Volume 6 | Issue 8 | e1001084Appraisal of the literature strongly suggests that in addition to
targeting similar brain areas and causing similar clinical
syndromes, DAergic neurodegeneration associated with PD or
PD-mimicking drugs (6-hydroxydopamine/6-OHDA, 1-methyl-4-
phenylpyridium/MPP+, rotenone, paraquat) and Mn neurotoxic-
ity share multiple common effector mechanisms, namely mito-
chondrial dysfunction, ATP depletion, aberrant signal transduc-
tion, oxidative stress, protein aggregation and the activation of cell
death pathways [32]. Damage to DAergic nigral neurons that is
induced by MPP+ and rotenone involves oxidative stress [33].
Oxidative damage also plays a significant role in 6-OHDA-
induced DAergic neuronal cell death. In cell cultures, hydrogen
peroxide (H2O2), superoxide ions and hydroxyl radicals [34]
generated by the non-enzymatic breakdown of 6-OHDA and the
direct inhibition of complex-I activity, lead to lipid peroxidation,
protein denaturation and a decrease in glutathione (GSH), all
hallmark features of post-mortem PD [35,36,37].
Intrastriatal Mn injections result in the loss of DAergic neurons,
a process in which oxidative stress plays a significant role
[38,39,40], resembling toxicity caused by the mitochondrial
poisons, aminooxyacetic acid and MPP
+ [41]. Similarly to
mitochondrial inhibitors such as MPP
+ [42], Mn increases in vivo
synaptic glutamate concentrations, which leads to excitotoxic and
oxidative injury [43] and interfers with ATP synthesis [44].
Analogous to MPP
+ and 6-OHDA, Mn elevates intracellular
H2O2 and related peroxides [45] and reduces tyrosine hydroxylase
(TH) activity and intracellular antioxidant levels (GSH, thiols,
catalase) in DAergic neurons [43,46,47,48]. Intracellular Mn
2+
inhibits the mitochondrial complex-I, a feature inherent to PD and
its experimental models (MPP
+, 6-OHDA, rotenone, paraquat)
[43]. A link between mitochondrial impairment, oxidative stress
and increased a-synuclein aggregation is well documented for Mn
and in various models of PD [37,43,49,50,51]. Studies have also
confirmed that treatment with Mn in a pre-parkinsonian state (6-
OHDA) significantly exacerbates neurobehavioral impairment in
the rat, not only suggesting that Mn exposure may increase the risk
of injury in subpopulations that are in a pre-parkinsonism state,
but also pointing to the convergence of signaling pathways that
lead to such injury [52].
MPP
+ and 6-OHDA exposures as well as wild-type or mutant a-
synuclein overexpression cause specific DAergic neurodegenera-
tion in the worm [53,54,55,56], a process which involves ATP
depletion and oxidative stress [36,57,58], analogous to vertebrate
models of PD. It was further confirmed that C. elegans orthologues
of PD-associated genes play a role in a-synuclein toxicity and
DAergic neurodegeneration. Additionally, conserved genetic
networks were identified in C. elegans that potentiate or protect
against a-synuclein toxicity, such as the torsin pathway
[36,59,60,61,62,63,64]. A link between a-synuclein and Mn
toxicity was also demonstrated in the worm [59,65]. Furthermore,
we previously established that Mn uptake and toxicity pathways in
C. elegans relate to those described in vertebrates, which involves
the NRAMP/DMT family of metal transporters and leads to
defects in the developmental and excretory systems [66]. Here we
show that at a sub-lethal range of concentrations, acute Mn
exposure leads to a specific and dose-dependent neurodegenera-
tion of all C. elegans DAergic neurons, while sparing other
neurotransmitter systems, findings that corroborate the specificity
of DAergic sensitivity shared with vertebrate models. We
investigated the causes of this DAergic specificity, and we
demonstrated that endogenous extracellular, but not intracellular
DA potentiates Mn toxicity and that Mn-induced neurodegener-
ation requires the DAergic neuron-specific dopamine re-uptake
transporter, DAT-1. We also found that Mn toxicity in the worm
is associated with increased reactive-oxygen species (ROS), lipid
peroxidation and lifespan reduction, all of which were dependent
on extracellular DA concentrations. Additionally, we observed a
relocation of the oxidant-responsive transcription factor, SKN-1,
in ASI nuclei upon Mn exposure, whereas SKN-1 overexpression
afforded protection against Mn-induced toxicity. Finally, we
identified the NADPH dual-oxidase, BLI-3, as a key mediator of
the DA-dependency of Mn toxicity, suggesting that BLI-3
potentiates the formation of ROS from DA-derived species
obtained through the reaction of divalent Mn and extracellular
DA.
Results
C. elegans DAergic neurons degenerate in a specific and
concentration-dependent manner upon exposure to Mn
We first ascertained the suitability of Mn-exposed C. elegans as
an in vivo model for manganism and PD and examined whether
features inherent to mammalian DAergic neurodegeneration can
be convincingly recapitulated in this model. We took advantage
of the BY200 strain, which expresses the green fluorescent
protein (GFP) under the control of the DAergic-specific
dopamine re-uptake transporter 1 promoter, dat-1::GFP(vtIs1)
(Figure 1A). After acute exposure to Mn, a dose-dependent
neurodegeneration was observed in all DAergic neurons, namely
the 4 CEP, 2 ADE, 2 PDE and the male specific R5A, R7A and
R9A pairs of neurons (Figure 1A and 1B). Typically, the primary
defects were observed in neuron extensions, such as CEP
mechanosensory processes, resulting in discontinued and punc-
tuated GFP labeling (Figure 1A, 1B, 1D, arrowheads). With an
increased dose (Figure 1D, upper to lower panels) or longer
exposure to Mn (data not shown), these defects were exacerbated,
leading to shortening or disappearance of the neuronal extensions
(Figure 1D, lower panels) and eventually neuronal death as
revealed by the shrinkage of the cell body, and ultimately,
complete loss of GFP (data not shown, Figure 2A left panel). This
Author Summary
In Parkinson’s disease (PD), motor neurons that produce
dopamine degenerate, leading to a characteristic syn-
drome including tremor, rigidity, and bradykinesia. The
mechanisms leading to PD have been under intense
investigation, identifying hereditary mutations responsible
for about 8% of the cases. However, multiple environ-
mental factors contribute to PD; and, amongst those,
manganese (Mn) exposure from pesticides, industrial
fumes, and gasoline additives has been robustly associated
with PD. To gain insights into processes leading to the
specific degeneration of dopaminergic neurons, we used a
simple animal model, the nematode Caenorhabditis
elegans, which, upon Mn exposure, recapitulates key
molecular processes known to be involved in PD.
Combining biochemistry and genetics, we demonstrate
that dopamine secreted by the neurons and not intracel-
lular dopamine is directly involved in the generation of
toxic reactive oxygen species. We identify two essential
mediators of this dopamine-dependent effect which are an
extracellularly active enzyme called dual-oxidase and the
dopamine re-uptake transporter. We also reveal that a
transcription factor which is strongly expressed in two
neurons involved in the regulation of aging is a powerful
modulator of the dopamine-dependent toxicity. Our study
establishes novel evidence of the link among PD, aging,
and oxidative stress within the context of exposure to Mn.
BLI-3/Dopamine-Dependent Mn-Induced Neurotoxicity
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in GABAergic, cholinergic, glutamatergic (Figure 1C) or in other
biogenic-amine systems (data not shown). Despite the direct
exposure of chemosensory neurons to the Mn-containing
solution, DiI staining in these neurons failed to reveal any
degeneration (Figure 1C), confirming the specificity of the Mn-
induced DAergic neurodegeneration.
DAergic neurodegeneration requires the DA re-uptake
transporter DAT-1
The selectivity of Mn-induced neurodegeneration to DAergic
neurons suggests that some factor(s) specific to these neurons
sensitize(s) them to Mn-induced toxicity. To determine which
factor(s) may account for this effect, a candidate gene approach
was employed, starting with a gene known to be specific to the
DAergic neurons, namely, dat-1. DAT-1 is the C. elegans orthologue
of the vertebrate DAT, which is a highly conserved member of a
family of transporters involved in neurotransmitter clearance,
including the GABA re-uptake transporters, the GATs, the
serotonin re-uptake transporter, SERT, and the excitatory
amino-acid transporters, the EAATs. DAT is specifically respon-
sible for DA clearance at the synapse, removing excessive
extracellular DA into presynaptic DAergic termini [67,68,69].
Accordingly, chemical inhibition of DAT or DAT loss-of-function
leads to high extracellular DA levels [70,71]. In C. elegans, the dat-
1(ok157) loss-of-function mutant displays a swimming-induced
Figure 1. Dopaminergic neurons specifically degenerate in a dose-dependent manner upon Mn acute exposure. (A) Mechanosensory
termini of the CEP and ADE dopaminergic neurons in dat-1::GFP expressing worms display discontinuous GFP staining 24 h after 50 mM Mn acute
exposure at L1, revealing their degeneration. (B) Adult CEP, ADE, PDE and male specific R5A, R7A and R9A pairs of neurons are also affected following
50 mM MnCl2 acute exposure at L1. (C) GABAergic (unc-47::GFP), cholinergic (unc-17::GFP) and chemosensory neurons (DiI) are not affected by Mn
exposure at concentrations inducing dopaminergic neurodegeneration (50 mM here). (D) CEP and ADE degeneration upon Mn exposure is
dependent on Mn concentration. White arrowheads indicate neuronal processes exhibiting abnormal discontinuous GFP signal. White stars indicate
the position of degenerated neuron cell bodies.
doi:10.1371/journal.pgen.1001084.g001
BLI-3/Dopamine-Dependent Mn-Induced Neurotoxicity
PLoS Genetics | www.plosgenetics.org 3 August 2010 | Volume 6 | Issue 8 | e1001084paralysis (SWIP) phenotype, likely due to the hyper-activation of
DA-responsive motorneurons exposed to excessive synaptic DA
concentrations [71]. C. elegans dat-1 is also required for 6-OHDA
DAergic neuron toxicity as noted in dat-1::GFP transgenic worms
[56]. Given the specific neurodegeneration of dat-1::GFP-express-
ing neurons upon 6-OHDA or Mn exposure, we hypothesized that
dat-1 is required for Mn-induced DAergic degeneration. Accord-
ingly, dat-1(ok157) worms expressing dat-1::GFP were exposed to
graded Mn doses in parallel with wild-type worms expressing the
same dat-1::GFP array, and both strains were scored for DAergic
neuron defects. Mn treatment was associated with marked
DAergic neurodegeneration in wild-type worms, while dat-1
mutant DAergic neurons were not significantly affected even at
the highest doses of Mn (Figure 2A) exposure for which fewer than
5% of the worms survived (Figure 2B). Accordingly, dat-1 mutant
worms exposed to Mn most likely died from osmoregulation
defects before displaying any neurodegeneration in DAergic
neurons. These results established that DAergic neurodegenera-
tion in Mn-exposed worms requires a functional DAT-1
transporter.
Figure 2. dat-1 loss of function induces an overall hypersensitivity to Mn toxicity, but confers neuroprotection to the dopaminergic
system. (A) Most surviving dat-1::GFP expressing dat-1(ok157) mutants fail to exhibit dopaminergic neurodegeneration, while surviving dat-1::GFP
expressing wild-type worms always display dopaminergic processes loss and cell body shrinkage upon 150 mM Mn acute exposure. (B) dat-1::GFP
expressing dat-1(ok157) mutants are hypersensitive (p,0.001) to Mn exposure, with a LD50=17 mM. C) dat-1(ok157) is hypersensitive (p,0.001) to
Mn-induced lethality, with a LD50=9 mM.
doi:10.1371/journal.pgen.1001084.g002
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Mn-induced toxicity
Additional studies showed that the protective effect of dat-1 loss-
of-function on DAergic neurodegeneration was not due to an
indirect effect, such as an adaptive mechanism resulting in reduced
Mn-uptake. First, the lethal dose 50 at 24 h (LD50, dose of Mn
exposure at which 50% of the animals die from the treatment) for
both transgenic strains, dat-1(ok157); dat-1::GFP and dat-1(+); dat-
1::GFP, was determined. Notably, the dat-1(ok157); dat-1::GFP
strain showed significant hypersensitivity (p,0.001) to Mn-
induced toxicity with a LD50=20 mM, whereas the dat-1(+);
dat-1::GFP strain exhibited a LD50=74 mM (Figure 2B). Next, the
non-transgenic dat-1(ok157) and the N2 wild-type strains were
treated with the same range of Mn doses (0.001 mM to 1 M). Both
non-transgenic strains were slightly more sensitive than the
corresponding dat-1::GFP-expressing strains (Figure 2C). This
‘‘protective effect’’ of the transgene expression was not specific
to the dat-1::GFP construct and was systematically observed with
any type of transcriptional GFP-expressing construct (data not
shown). Transgenic worms may experience higher basal levels of
stress associated with increased stress-response protein levels,
enabling them to better cope with environmental stress. Never-
theless, dat-1(ok157) mutants exhibited hypersensitivity to Mn-
induced lethality (p,0.001), which was characterized by a
LD50=9 mM as compared to a LD50=47 mM for wild-type
worms (Figure 2C). This observation rules out the possibility that
dat-1(ok157) takes up less Mn. Moreover, it shows that upon Mn
exposure, DAT-1 loss-of-function is detrimental to worm survival,
though protective to DAergic neurons.
Sub-lethal exogenous DA pre-treatment potentiates Mn
toxicity
The importance of a functional DAT-1 in conferring selective
neurodegeneration in C. elegans DAergic neurons upon acute Mn
exposure reflected upon earlier work with the PD-mimicking drug
and DA analogue, 6-OHDA. Indeed, 6-OHDA induced a dose-
dependent DAergic neurodegeneration in C. elegans, which was
prevented by DAT-1 mutations [56,72]. The fact that both Mn
and 6-OHDA induce neurotoxicity through DAT-1 raises a
question regarding the relationship between Mn and DA
analogues upstream of DAT-1 in the DAergic neurodegeneration
pathway. It has been hypothesized that Mn, in its divalent or
trivalent cationic form, like iron, reacts with biogenic amines, such
as DA, to generate ROS [73,74,75]. It is also known that DA and
its derivatives, such as L-DOPA and 6-OHDA, can be toxic to the
mammalian DAergic system and can lead to intracellular oxidative
stress alone or in combination with metals and ensuing DAergic
neurodegeneration [46,76,77]. Accordingly, we hypothesized that
DA and Mn have a synergistic toxic effect in the worm. To test this
hypothesis, worms were acutely treated with 10 mM DA prior to
Mn exposure. DA pre-treatment led to a significant leftward shift
in the Mn dose-response survival curve (p,0.001) with a
LD50=25 mM (Figure 3A), while 10 mM acute DA treatment
alone did not affect the worms’ survival (Figure 3B). These results
establish that exogenously applied DA and Mn can act
synergistically in vivo to promote increased toxicity in the worm.
Endogenous DA potentiates Mn toxicity
In certain mutant backgrounds, such as vertebrate DAT
mutants, DA levels were reported to be abnormally elevated due
to a lack of DA clearance at the DAergic synapses [71]. Therefore,
the effect of DAT-1 loss-of-function on Mn sensitivity may reflect
increased endogenous levels of DA (Figure 4A). To test this
hypothesis, we measured DA levels in the C. elegans dat-1(ok157)
mutants. We found that dat-1(ok157) endogenous DA levels were
significantly higher when compared with wild-type worms
(Figure 4B). To confirm the role of endogenous DA in Mn
toxicity, we tested the effect of endogenous DA depletion on Mn
sensitivity using the cat-2(e1112) loss-of-function mutant, in which
the tyrosine hydroxylase (TH) activity is abolished, resulting in the
absence of DA synthesis (Figure 4A and 4B). cat-2(e1112) mutants
exposed to Mn revealed significant hyper-resistance (p,0.001),
with a LD50=95 mM (Figure 4C). Moreover, the e1112 deletion
rescued the dat-1(ok157) hypersensitivity (LD50=9 mM, Figure 3A)
and led to hyper-resistance to Mn (p,0.001) with a
LD50=83 mM for cat-2(e1112);dat-1(ok157) worms (Figure 4C).
The LD50 difference between cat-2(e1112) and cat-2(e1112);dat-
1(ok157) worm strains was not statistically significant (p.0.05),
suggesting that the cat-2(e1112) effect takes place upstream of dat-
1(ok157) in the same pathway (Figure 4A). Finally, we supple-
Figure 3. Sub-lethal dopamine pre-treatment sensitizes wild-type worms to Mn exposure. (A) Pre-treatment with 10 mM dopamine
renders wild-type worms hypersensitive (p,0.001) to subsequent MnCl2 exposure, bringing the LD50 from 47 mM to 25 mM. (B) 10 mM L1 acute
treatment does not affect wild-type worm survival at 24 h.
doi:10.1371/journal.pgen.1001084.g003
BLI-3/Dopamine-Dependent Mn-Induced Neurotoxicity
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treatment, which rendered those mutants hypersensitive (p,0.001)
to Mn with a LD50=34 mM (Figure 4C). Pre-exposure to 10 mM
DA of cat-2(e1112);dat-1(ok157) worms led to a comparable
LD50=40 mM, not significantly different from cat-2(e1112)
mutants pre-exposed to 10 mM DA, but significantly different
Figure 4. Increased extracellular, but not intracellular, dopamine levels confer hypersensitivity to Mn toxicity while decreased
levels are protective. (A) Schematic representation of a generic dopaminergic synapse in C. elegans. (B) Total DA levels in selected mutants
relevant to the study at the L1 larval stage. dat-1(ok157), dop-2(vs105);dop-1(vs100) dop-3(vs106) display significantly (p,0.001) higher dopamine
levels than WT or other mutants, while dopamine measurement in cat-2(e1112) and dat-1(ok157);cat-2(e1112) did not reach a significant value
compared to the background levels measured in our experiment. (C) dat-1(ok157) is hypersensitive (p,0.001) to Mn-induced lethality, with a
LD50=9 mM. cat-2(e1112) is hyper-resistant (p,0.001) to Mn-induced lethality, with a LD50=95mM. cat-2(e1112) rescues dat-1(ok157)
hypersensitivity in the double-mutant cat-2(e1112); dat-1(ok157), which LD50=83 mM is not significantly different from cat-2(e1112) mutant.
10 mM DA pre-treatment restores Mn sensitivity (p,0.001) in both cat-2(e1112) and cat-2(e1112);dat-1(ok157), with respective LD50 of 34 mM and
40 mM. (D) The VMAT2 mutant cat-1(e1111) exhibits hyper-resistance to Mn (p,0.001), with a LD50=108 mM; while the DA receptor mutant dop-
2(vs105);dop-1(vs100) dop-3(vs106) is hypersensitive to Mn exposure (p,0.001), with a LD50=27 mM.
doi:10.1371/journal.pgen.1001084.g004
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(Figure 4C). These data further confirm that endogenous DA
level regulation plays a key role in Mn toxicity and that DA itself is
required for the full extent of Mn toxicity.
Extracellular DA, and not intracellular DA, is involved in
Mn-induced lethality
Next, we determined which step along the DAergic metabolic
pathway contributes to the synergistic toxic effect of Mn. To
address this issue, endogenous DA levels at the L1 stage were
measured in a combination of deletion mutants (Figure 4A). First,
we sought to determine if DA release was necessary for the DA-
dependent Mn-induced lethality. Accordingly, cat-1(e1111) mu-
tants in which the vesicular monoamine transporter 2 (VMAT2) is
defective, were exposed to Mn (Figure 4B). This mutant is unable
to pack DA in secretory vesicles, thus abolishing DA synaptic
release, while still producing normal levels of DA, at least at the L1
stage (Figure 4A). Upon exposure to Mn, cat-1(e1111) mutants
were more resistant to Mn-induced lethality than wild-type worms
(p,0.001), with a LD50=108 mM (Figure 4D), which was
statistically insignificant when compared to the cat-2(e1112)
mutant LD50 (p.0.05). These data establish that synaptic DA
release is necessary for DA-dependent Mn-induced lethality and
that extracellular DA, and not presynaptic DA, mediates this
effect.
Furthermore, the data imply that blockage of extracellular DA
receptor activity (and the ensuing increase in extracellular DA
levels) should exacerbate Mn sensitivity. C. elegans expresses three
DA receptors, namely DOP-1, DOP-2 and DOP-3 (Figure 4A). A
triple knock-out was generated [78], and as expected, the dop-
2(vs105); dop-1(vs100) dop-3(vs106) mutant exhibited higher levels
of DA (Figure 4B) and was hypersensitive (p,0.001 vs. wild-type)
to Mn-induced lethality with a LD50=27 mM (Figure 4D).
However, this mutant was not as sensitive to Mn as the dat-
1(ok157) mutant, probably because the DA clearance activity of
the wild-type DAT-1 limited the extent of the extracellular DA
accumulation in the dop-2(vs105); dop-1(vs100) dop-3(vs106) triple
mutant. These results confirm that extracellular, and not
intracellular DA is responsible for the DA-dependent Mn-induced
lethality.
DA-dependent Mn toxicity is associated with decreased
longevity
To further investigate the pathways involved in the DA-
dependent Mn toxicity, and especially its long-term effects, we
scored the survival rate of worms which survived acute Mn-
exposure. For each strain tested, we picked healthy-looking young
adults homogeneous in stage at 48 h post-exposure (for all strains
tested these animals were representative of more than 90% of the
surviving population), and disregarded sick-looking or develop-
mentally delayed worms. Accordingly, all animals selected
survived at least 4 days in adulthood, regardless of their genetic
background. This bias was deemed necessary to ensure that any
significant differences potentially observed between strains could
not be attributed to early toxicity events. In accordance with
previous reports [79], low doses of Mn (3 mM for 30 min) led to
a minor (albeit insignificant) increase in the surviving wild-type
lifespan from 14.5 days post-treatment (dpt) to 15 dpt (Figure 5A,
upper and middle graphs). Higher doses of Mn (100 mM for
30 min) led to a decrease in lifespan from 14.5 dpt to 13.8 dpt
(p,0.001, Figure 5A, bottom graph). dat-1(ok1057) mutants
exhibited a significantly shorter lifespan compared with wild-type
worms in the absence of Mn treatment (13.2 dpt, p,0.001),
which was further reduced (p,0.001) by both low- and high-dose
acute Mn treatments (12 dpt and 11.7 dpt, respectively).
Conversely, the lifespan of short-lived cat-2(e1112) mutants
(12.3 dpt in absence of Mn, p,0.001) was significantly increased
with increased Mn dosing (p,0.001, 14.6 dpt upon 3 mM and
14.8 dpt upon 100 mM acute Mn exposure). Moreover, the
lifespan of the cat-2(e1112) mutants was significantly extended as
compared to wild-type worms upon 100 mM Mn exposure (14.8
dpt vs 13.8 dpt, p,0.001), reaching untreated wild-type worm
average lifespan (14.8 dpt vs 14.5 dpt). These observations made
on worms, all of which survived for at least 5 days post-treatment,
mirror the results obtained for lethality rates at 24 h post-
treatment, indicating that the DA-dependent Mn toxicity
observed upon acute Mn treatment has short- and long-term
components, affecting both developmental (see also [66]) and
aging processes.
DA-dependent Mn-induced toxicity is associated with
increased oxidative stress
Toxicity mechanisms implicated in neurodegenerative diseases,
such as PD and Alzheimer’s disease, involve oxidative stress
[32,35,37,80,81,82,83]. In particular, DAergic cell loss in PD
patients and experimental PD models invokes excessive ROS
production [77,84,85,86,87,88]. Moreover, oxidizing metals such
as copper, Mn and iron in their 2+ or 3+ states are known to be
sources of ROS via the Fenton reaction [89]. In C. elegans, pre-
treatment with anti-oxidants such as ebselen, affords protection
against acutely-induced Mn toxicity (Avila and Aschner,
unpublished data). To determine if oxidative stress plays a role
in DA-dependent Mn toxicity in C. elegans, a double-pronged
approach was undertaken. First, the presence of ROS in response
to acute Mn treatment was determined with the fluorescent dye,
2979 dichlorodihydrofluorescein diacetate (H2DCF-DA). As
shown in Figure 5B, Mn-treated wild-type worms showed a
significant (p,0.05) increase in fluorescence at sub-lethal Mn
doses (10 mM). Interestingly, dat-1(ok157) mutants showed a
significant increase in fluorescence (p,0.01) after 1 mM
exposure, whereas cat-2(e1112); dat-1(ok157) double mutants did
not show any significant increase in fluorescence (p.0.05) upon
exposure up to 30 mM Mn (Figure 5B). To confirm these results,
we also used a more quantitative method involving the
measurement of lipid peroxidation. Isoprostanes F2 (F2IP) and
F3 (F3IP) are oxidation products of arachidonic acid (AA), which
is released from membranes upon oxidative injury [90,91,92]. A
new protocol was developed to extract and measure F2IP and
F3IP from C. elegans. Corroborating the H2DCF-DA results
(Figure 5B), dat-1(ok157) mutants exhibited significantly higher
levels of F2IP (Figure 5C) and F3IP (data not shown) upon 1, 3
and 5 mM Mn exposure (p,0.05, p,0.001, p,0.05, respective-
ly), as compared to wild-type worms, which showed a significant
increase in F2IP content upon 5 and 10 mM Mn exposure
(p,0.05 and p,0.001, respectively) (Figure 5C). The double
mutant cat-2(e1112);dat-1(ok157) consistently displayed decreased
F2IP levels between 1 and 5 mM Mn, with significantly lower
levels at 3 mM (p,0.05), and exhibited significantly higher F2IP
levels upon 10, 20 and 30 mM acute Mn exposure (p,0.05,
p,0.01, p,0.001, respectively) (Figure 5C). Thus, to attain
maximal levels of F2IP (corresponding to a 2-fold increase),
higher doses of Mn were required in cat-2(e1112);dat-1(ok157)
mutants compared to wild-type and in wild-type compared to dat-
1(ok157). Taken together, the H2DCF-DA and isoprostane
measurements show that acute Mn treatments induce oxidative
stress in C. elegans. In addition, the degree of oxidative stress
depends on the extracellular DA content. These experiments
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involves oxidative stress.
The anti-oxidant transcription factor, SKN-1, protects
against Mn toxicity and relocalizes in amphide sensilla
ASI neuron nuclei upon Mn exposure
An alternative functional way to establish oxidative stress,
especially in its earliest stages, is to demonstrate a physiological
response to it. Sodium arsenite exposure in C. elegans has
previously been shown to induce a strong intestinal expression
of the anti-oxidant response gene, skn-1, the orthologue of the
vertebrate gene, Nrf2 [93]. SKN-1 initiates the development of
the digestive system and feeding during the earliest embryonic
stages, and post-embryonically, is required for a normal lifespan
and adequate resistance to stress [94,95,96]. Consistent with
these observations, skn-1 deletions or loss-of-function mutations
suppress oxidative stress resistance [97]. Aging in C. elegans is
delayed when SKN-1 is transgenically expressed, and a mutant
skn-1 form that constitutively localizes to nuclei increases the
worm’s lifespan [94,97,98,99]. To determine if SKN-1 can afford
protection against Mn toxicity and to confirm that oxidative stress
plays an important role in Mn-induced toxicity in C. elegans,
SKN-1::GFP over-expressing worms were exposed to Mn. These
worms exhibited a strong hyper-resistant phenotype to Mn
exposure with a LD50=114 mM (Figure 6A). This effect was
significantly greater in comparison to wild-type (p,0.001) or
GFP expression alone (p,0.01) under various promoters (cf. dat-
1::GFP, Figure 2; data not shown) despite the aforementioned
protective effect of GFP expression, suggesting that SKN-1
directly protects against Mn toxicity. Moreover, a mixed
population of two-third heterozygous and one-third homozygous
deletion-mutant skn-1(ok2315) expressing a truncated SKN-1
protein, exhibited increased sensitivity to Mn exposure with a
LD50=34 mM (Figure 6A), confirming that SKN-1 is required
for mediating optimal resistance to Mn exposure. Unexpectedly,
Figure 5. Dopamine-dependent Mn toxicity is associated with decreased lifespan and increased oxidative stress. (A) cat-2(e1112) and
dat-1(ok1057) mutants both show a reduced lifespan (p,0.001) upon Mn acute treatment. dat-1(ok1057) exhibit a further reduced lifespan, whereas
cat-2(e1112) show a significant improvement upon 3 mM MnCl2 acute treatment and a further increased lifespan (p,0.001) upon 100 mM MnCl2
acute treatment. Plotted values represent averages of three independent experiments and the curves represent the best sigmoidal fit. (B) Wild-type
worms exhibit significantly higher reactive oxygen species (ROS) levels upon 10 mM Mn treatment (p,0.05), while dat-1(ok157) mutant show a
significant increase after only 1 mM Mn exposure (p,0.01), and cat-2(e1112);dat-1(ok157) display normal ROS levels up to 30 mM Mn exposure. (C)
Wild-type worms display significantly increased isoprostane-2 (F2IP) levels upon 10 mM Mn treatment (p,0.001), while dat-1(ok157) mutant show a
significant increase after 3 mM Mn exposure (p,0.001), and cat-2(e1112);dat-1(ok157) upon 20 mM (p,0.05) and 30 mM (p,0.01).
doi:10.1371/journal.pgen.1001084.g005
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noted upon Mn exposure, possibly because SKN-1 was already
over-expressed or because it is not activated by Mn. However, a
notable change in the SKN-1::GFP localization pattern in the
ASI neuron was associated with Mn exposure, where SKN-
1::GFP relocalized in discrete nuclear puncta, a result distinctly
different from the diffuse pattern exhibited in non-Mn exposed
worms (Figure 6B). This change was associated with a
significantly increased average nuclear density of SKN-1::GFP
(p,0.05, Figure 6C) but a non-significant increase in ASI
expression, as revealed by the integral GFP intensity measure-
ments (Figure 6D). These results support the notion that Mn
exposure triggers an increase in ROS levels, thus activating the
antioxidant response pathway, at least in ASI neurons. The data
also indicate that the nuclear relocation of SKN-1, rather than its
increased expression, is responsible for this protective effect
against Mn toxicity.
The dual-oxidase mutant bli-3(e767) is resistant to
DA-dependent Mn toxicity
Given that Mn induces DA-dependent oxidative stress, we next
sought to identify genetic factors involved in this process. In
addition to the mitochondrial electron-transport chain (ETC),
plasma membrane NADPH oxidases are major contributors to
ROS production in rotenone, paraquat and MPP+-induced
toxicity [86,100,101,102,103]. The bli-3 gene encodes a C. elegans
dual-oxidase orthologue to vertebrates DUOX1 and DUOX2,
which is involved in the di-tyrosine bond formation in the worm
cuticle [104] and pathogen-induced ROS production [105,106].
Di-tyrosine bonds maintain cuticle integrity, and bli-3(e767)
mutants display a blistered cuticle and a mild dumpy phenotype.
This phenotype renders worms more sensitive to toxicants due to
increased absorbance of the toxicants through the damaged cuticle
[104]. Interestingly, bli-3(e767) worms displayed hyper-resistance
to acute Mn treatments when compared to wild-type worms
(p,0.001), with a LD50=83 mM (Figure 7A), suggesting that BLI-
3 is involved in mediating Mn-toxicity, most likely by potentiating
ROS production and oxidative stress. Notably, sub-lethal
(Figure 7B) DA pre-treatment did not affect bli-3(e767) worm
sensitivity to Mn: LD50=84mM (Figure 7A). Moreover, similar to
cat-2(e1112) mutants (Figure 5B), bli-3(e767) mutants did not show
any dose-dependent increase in ROS production from 1 mM to
30 mM Mn exposures (Figure 7C). ANOVA (comparing data
from Figure 5B and Figure 7C) reveals that bli-3(e767) mutants
Figure 6. skn-1 mutants are hypersensitive while SKN-1::GFP overexpressing worms are hyper-resistant to Mn toxicity and respond
to Mn exposure by relocalizing SKN-1::GFP to nuclear puncta in ASI neurons. (A) SKN-1::GFP expressing worms are hyper-resistant
(p,0.001) to Mn-induced lethality, with a LD50=114 mM, while mixed skn-1(ok2315) and skn-1(ok2315)/+ are hypersensitive (p,0.001) to Mn
exposure, with a LD50=34 mM. (B) SKN-1::GFP nuclear localization in ASI neurons reorganizes in puncta 1 hour after MnCl2 exposure. (C) SKN-1::GFP
mean brightness significantly increases (p,0.05) in ASI nuclei upon Mn exposure while integral brightness does not (D).
doi:10.1371/journal.pgen.1001084.g006
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1(ok157) worms at 3 mM (p,0.001) and compared to wild-type
worms at 10 mM (p,0.01), but no difference compared to cat-
2(e1112) worms at any Mn concentration tested.
These observations strongly support the notion that BLI-3 is
required for the ROS-associated potentiating effect of DA in Mn
toxicity. Given the structural analogy between DA and tyrosine,
DA or DA-derived species formed upon reaction with Mn may
serve as substrates for BLI-3, facilitating their conversion to highly
oxidized species, and in turn, potentiating oxidative stress.
Discussion
This study establishes that Mn induces a specific and dose-
dependent neurodegeneration of DAergic neurons in C. elegans,
corroborating findings in rodents and non-human primates. This
neurodegeneration was proven to require the DA re-uptake
transporter, DAT-1, which is also the case in 6-OHDA-induced
neurotoxicity. Combined, these observations suggest that upon Mn
exposure, DAT-1 facilitates the intracellular transport of toxic
species into DAergic neurons. Mn toxicity was associated with
increased ROS generation and elevated F2IP levels as well as
reduced longevity,allofwhichwereaggravated byhighendogenous
DA levels and were attenuated by DA depletion. Consistent with a
Mn-induced increase in oxidative stress, nuclear relocation of the
anti-oxidanttranscriptionfactor,SKN-1,was notedinASIneurons,
and SKN-1 overexpression afforded protection against Mn-induced
toxicity, while skn-1 deletion rendered worms more vulnerable to
Mn toxicity. Increased extracellular, but not intracellular DA levels
resulting from direct DA exposure or genetic manipulation
potentiated Mn-induced lethality, oxidative-stress and reduction
in lifespan. Finally, our studies establish that the dual-oxidase, BLI-
3, is involved in the DA-dependent Mn-induced toxicity and that
bli-3 loss-of-function suppresses the DA-dependency of Mn toxicity
and associated oxidative stress. Combined, these data suggest that
oxidation of extracellular DA promoted by the BLI-3 dual-oxidase
activity triggers DA-derived ROS generation, which, in turn, are
taken up into the DAergic terminals by DAT-1 and lead to specific
DAergic neurodegeneration (Figure 8).
Relevance of our findings to the study of manganism and
PD in mammalian models
Mn-treated C. elegans recapitulate essential physiological aspects
of parkinsonism, namely: the importance of NRAMP/DMT
orthologues in the toxicity process [107,108,109]; the specificity
Figure 7. bli-3 loss of function is hyper-resistant to Mn toxicity, insensitive to dopamine pre-treatment, and exhibits no dose-
dependent Mn-associated ROS production. (A) bli-3(e767) is hyper-resistant (p,0.001) to Mn-induced lethality, with a LD50=83 mM. Pre-treatment
with 10 mM dopamine (DA) does not change its hyper-resistance(p,0.001)and its LD50=84 mM is not significantlydifferent from animals that were not
pre-treated. (B) DA pre-treatment does not affect bli-3(e767) survival at 24 h. (C) Mn exposures from 1 mM up to 30 mM do not affect ROS levels
significantly in bli-3(e767) worms (p.0.1). D) bli-3(e767) mutant does not show any significant difference in ROS levels upon Mn exposure up to 30 mM.
doi:10.1371/journal.pgen.1001084.g007
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[110,111]; the involvement of DAT [112,113,114]; the synergy
between DA and Mn [115]; and the associated oxidative stress
[116,117,118].
As many divalent metallic cations are able to oxidize biogenic
amines (amongst which DA and serotonin) in vitro via the Fenton’s
reaction, we carried out two control experiments to ascertain the
specificity of the relationship between DA and Mn in vivo. Unlike
dat-1 mutation, deletion of the serotonin transporter (mod-5 in C.
elegans) did not affect Mn-induced lethality (LD50=45 mM, Figure
S1), and DA-depleted cat-2(e1112);dat-1(ok157) mutants revealed
greater susceptibility to iron-induced ROS production (p,0.05)
than wild-type worms (Figure S2), supporting the fact that in vivo,
metal-induced DA-dependent toxicity is specific to Mn. An
additional novelty resides in the finding of the early and central
role played by endogenous extracellular DA and the NADPH
dual-oxidase in Mn-induced toxicity (Figure 4, Figure 5, and
Figure 7). The centrality of extracellular DA in Mn-induced
toxicity was further exemplified by the level of resistance to Mn
conferred by mutations in cat-1 (LD50=108 mM) and cat-2
(LD50=95 mM), which approach those conferred by deletion of
the Mn transporter, smf-3 (LD50=126 mM) [66]. Moreover, Mn
in its normal toxic range had a strong beneficial effect on the
lifespan of DA-depleted cat-2(e1112) mutants (Figure 5A), further
confirming that the DA-dependent component of Mn-induced
toxicity accounts for a significant share of the overall toxicity.
Importantly, the hypersensitivity to Mn of the DA receptor triple-
knockout (Figure 4D), shows that Mn-induced neurodegeneration
does not require DA receptors. Combined with the absence of
post-synaptic neurodegeneration in dop-1::GFP and dop-3::RFP-
expressing worms upon Mn exposure (data not shown) and despite
the excitotoxic potential of other DA-related compounds, such as
L-DOPA and 6-OHDA [119], the results establish that DA-
dependent Mn toxicity does not involve excitotoxicity, in contrary
to the glutamate-induced neurodegeneration involved in amyo-
trophic lateral sclerosis (ALS) [120]. Together, these results also
provide a novel explanation for the requirement of DAT in the
DAergic neurodegeneration in vivo. Rather than being responsible
for cytosolic DA accumulation followed by downstream ROS
production, which was considered as the reason for the sensitivity
of DAergic neurons to PD-mimicking drugs (MPP
+, 6-OHDA)
[56,114,121,122], DAT may facilitate the transport of extra-
cellulary oxidized DA-derived species into DAergic neurons. In
man and rat, subchronic Mn exposure has been shown to reduce
DAT expression levels [123,124]. Although it is unclear if it
reflected a decline of DAergic neuron activity or a specific down-
regulation of DAT, Mn interference with DAT activity should be
further investigated. The importance of the NADPH dual-oxidase,
BLI-3, in the DA-dependent Mn toxicity in C. elegans corroborates
the up-regulation of its mammalian orthologue in PD patients and
MPP
+-exposed mice, as well as the protective effect conferred by
its loss-of-function against oxidative stress and DAergic neurode-
generation in MPP
+-exposed mutant mice [86]. Finally, DA-
dependent Mn-induced toxicity has both short and long-term
components as revealed by survival rate and oxidative stress
measurements at 24 h (Figure 4, Figure 5B and 5C) and by
lifespan data (Figure 5A). The protective effect afforded by SKN-1
upregulation upon Mn exposure and its nuclear relocation in ASI
neurons (Figure 6) emphasizes the influence of acute Mn
treatments on aging. ASI neurons which strongly express SKN-
1, were shown to play a key role in lifespan modulation through
the well-studied diet-restriction pathway [125]. Hence, further
examination of Mn-induced toxicity and lifespan reduction in ASI
neuron-ablated worms, skn-1(RNAi) worms and mutants of the
diet-restriction pathway may provide essential insights in the
relationship between aging and PD, as well as on the role of
specific brain area (corresponding to the C. elegans ASI neurons) on
aging and PD.
Despite the absence of an obvious PD-like behavior in the
worm, DAergic neurodegeneration in C. elegans induced either by
PD-drug treatment (6-OHDA, DA, MPP
+) or by Mn involves the
same key genes and molecular pathways as in vertebrates
[32,36,54,59,60,64,65,66,126,127,128], has both short-term and
long-term components and therefore represents a powerful model
Figure 8. Recapitulative scheme. Manganese taken up by the epithelial DMT1-like SMF transporters is released in the body cavity (possibly by
ferroportins), where it meets extracellular dopamine released from the dopaminergic synapses. The dual-oxidase BLI-3 is likely involved in the
generation of oxidized dopamine-derived species, which can be taken up by DAT-1 leading to dopaminergic neurodegeneration, or are further
increasing overall oxidative stress, associated with larval lethality and adult lifespan reduction. The ASI neurons in which SKN-1 nuclear relocation was
observed could be involved in the orchestration of the overall antioxidant response. Dashed arrows highlight the pathways supported by this study.
‘‘SMFs?’’: SMF transporters may be involved in direct Mn uptake in DAergic neurons according to earlier studies [65,66].
doi:10.1371/journal.pgen.1001084.g008
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manganism. To further demonstrate the relevance of our findings
to vertebrate physiology, it would be interesting to test (1) whether
co-treatments of DA and Mn lead to the same synergy in DAergic
neurodegeneration in rodents; (2) whether such synergy is
dependent on DAT; and (3) whether tyrosine hydroxylase (TH/
CAT-2) and VMAT inhibition affords neuroprotection. Establish-
ing the contribution of vertebrate NADPH dual-oxidases to the
oxidation state of DA in the absence or presence of Mn would also
be important. The present study also revealed DA-dependent
mechanisms of Mn-induced toxicity by focusing on a whole-
organism approach, while acknowledging that further investiga-
tion should also focus specifically on DAergic neuron physiology.
For instance, determining if upon Mn exposure, cat-2, cat-1 and
cat-2;dat-1 mutants display less or no neurodegeneration and if DA
supplementation can reverse this effect, would allow clearer
understanding of the role of DAT, and intracellular and
extracellular DA in the demise of the DAergic system. It would
also be important to develop full-length GFP-tagged protein
markers of the DAergic neurons as the dat-1::GFP probe can only
reveal relatively advanced stages of neuronal decay, and not more
subtle functional changes. This point is exemplified by the
observation of SKN-1::GFP relocation in ASI neurons (Figure 6),
which would have been missed if only a transcriptional GFP
reporter approach had been used. Finally, exploring the effect of
aging and diet-restriction modulated by the ASI neurons and the
Nrf2-like transcription factor, SKN-1, would enhance our
understanding of the pathophysiology and the progressive nature
of PD.
Further developments and implications for the treatment
of DAergic neurodegeneration
Given the similarities between Mn toxicity in C. elegans and in
vertebrates [66] as well as the great conservation of most PD-
related genes involved in DAergic neurodegeneration in rodents
and humans [32,36,59,60,64,129], it is likely that the DA-
dependent toxicity revealed herein plays an important role in
diseases associated with DAergic neuron loss in mammals. The
importance of extracellular DA levels in the toxicity mechanisms
described here, if corroborated in vertebrates, could bear
important implications for the treatment of DAergic neurodegen-
eration, as modulating extracellular vs. intracellular DA levels
requires different strategies. For instance, L-DOPA is prescribed in
PD and manganism patients to treat the tremor and bradykinesia
arising from the loss of DAergic activity. If L-DOPA, like DA, led
to the excessive generation of oxidized reactive species in vivo,L -
DOPA treatment, although compensating for the DA loss, could
accelerate or exacerbate the DAergic neurodegeneration over a
longer term. If the involvement of dual-oxidases in DA oxidation
was confirmed in vertebrates and if L-DOPA was shown to be
easily oxidized by dual-oxidases, it would be important to design
alternative DA analogues, which maintain high affinity for DA
receptors and DAT but are poor substrates for the dual-oxidases.
Another strategy to limit the extent of the DAergic neurodegen-
eration could be the direct inhibition of the dual-oxidases. Finally,
the protective effect of SKN-1 overexpression on Mn-induced
toxicity (Figure 6A), which mirrors the neuroprotection afforded
by astrocytic overexpression of Nrf2 in mice [130], suggests that
promoting Nrf2 activity may be beneficial in limiting Mn-induced
toxicity [131,132]. Such an approach would be particularly
relevant to welding and smelting activities in which workers
exposed to metal fumes have an increased risk of developing
parkinsonian syndromes [28,133,134,135,136].
Nature of the DA-derived oxidized species and oxidative-
stress pathways involved in PD
The current literature provides a conceptual framework for
addressing the synergistic mechanism of Mn and DA in DAergic
neurodegeneration [76,137,138,139,140,141]. Accordingly, Mn may
enter DAergic neurons via DAT as a complex with DA-derivatives,
such as dopaminochrome [138,141,142,143,144,145,146,147]. This
hypothesis provides explanations both for the specificity of Mn
toxicity towards DAergic neurons as well as for the synergistic
toxicity of extracellular DA and Mn, while remaining consistent
with studies that report a significant Mn uptake by the DAergic
neurons [148,149,150,151]. Purification and identification of the
DA-derived reactive species (using HPLC-ED [152]) are essential
for proving these suggestions. Further quantification of those DA-
derived species in Mn-, MPP
+-, 6-OHDA- and DA-exposed
worms or in the rodent brain and cerebrospinal fluid should help
identify the key toxic species in DAergic neurodegeneration as
well as point out candidate enzymes possibly involved in PD.
However, in biochemical approaches, the timing of extraction is
critical to robustly detecting and measuring those species. This
concern is exemplified by our oxidative stress marker measure-
ments in wild-type and dat-1(ok157) mutant worms (Figure 5B and
5C). Hence, above the Mn dose reaching the maximum increase
in ROS or F2IP levels, higher Mn doses led to lower oxidative
stress marker levels suggesting a decrease in oxidative stress, while
the lethality rate at 24 h and lifespan results suggest otherwise
(Figure 4, Figure 5A). It is unlikely that oxidative stress decreased
past the dose showing the maximum increase in oxidative stress
markers. Downstream conversion or degradation of ROS or F2IP
associated with a worsening of the condition of the worm may be
responsible for this effect. Using genetic backgrounds that stop or
delay the oxidative cascade at different steps of the pathway
would allow the accumulation of specific ROS and increase their
detection. Hence, Mn-resistant C. elegans mutants exposed to
medium- to high-dose treatments (in the 20 to 100 mM range)
could be very helpful in identifying the early steps of the oxidative
cascade(s) leading to DAergic neurodegeneration and could yield
new molecular targets for PD treatment. This study identifies a
few of the potential candidates (bli-3, SKN-1 overexpressing and
maybe cat-1 mutant worms, Figure 4 and Figure 6), but genetic
screens to isolate new Mn-resistant mutants would provide
powerful means for further investigation.
Role of Mn and DA in C. elegans longevity
In the course of this study, we came across several indications of
the influence of the DA-dependent and Mn-induced toxicity on C.
elegans longevity, which is unlikely to be a direct consequence of
DAergic neurodegeneration, but rather a concomitant effect (dat-
1(ok157) mutants did not show DAergic neurodegeneration,
whereas their lifespan decreased upon Mn exposure).
First, the fact that SKN-1 protects against Mn-induced toxicity
and modifies its nuclear localization pattern upon Mn exposure in
ASI neurons (Figure 6), provides a genetic link with the Insulin/
IGF-1 and caloric restriction pathway known to be involved in the
modulation of lifespan in C. elegans [97]. The nuclear relocation of
SKN-1 in ASI neurons in a punctuate pattern is suggestive of
binding of this transcription factor to specific chromosomal
regions, likely corresponding to the loci of its downstream targets.
Chromatine immunoprecipitation experiments could be used to
identify those loci, while generation of transgenic worms
expressing SKN-1::GFP and tagged sequences corresponding to
candidate gene (for instance the superoxide dismutase genes)
regulatory sequences would allow immuno-colocalization of
SKN-1 and its targets. Nrf2/SKN-1 is known to be a key
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its impact on lifespan could as well be due to its ability to reduce
oxidative stress naturally occurring with age, without involving
caloric restriction. Given the impact of Mn exposure and DA
metabolism on oxidative stress (Figure 5B and 5C), SKN-1
overexpression may improve Mn-exposed worm survival merely
by compensating for the excessive ROS produced when
extracellular DA levels are high and/or when Mn exposure
reaches toxicity levels. Interestingly, the survival dose-response
curve obtained with a non-null mutation (ok2315) in a mixed
population of heterozygous and homozygous animals (Figure 6A)
showed that even for very low doses of Mn (0.001 and 0.01 mM), a
noticeable fraction of the worms (about 15–20%) died at 24 h post
treatment compared to untreated animals, making it difficult to fit
the experimental data with a simple sigmoid dose-response curve.
As it is a mixed population, it is likely that mostly homozygous
mutants died at those lowest doses, suggesting that their LD50
could be in the submillimolar range, making skn-1(ok2315) worms
the most Mn-sensitive mutants tested so far. This requires direct
confirmation, but it further supports an essential role for SKN-1 in
regulating even slight changes in oxidative stress levels.
Second, our lifespan experiments showed that both dat-1 and
cat-2 mutants are short-lived in control conditions (no published
literature could be identified reporting on the lifespan of these
mutants) compared to wild-type worms (Figure 5A). According to
our ROS and isoprostane measurements (Figure 5B and 5C), dat-1
mutants show increased oxidative stress, which is known to worsen
with age; therefore explaining their shorter lifespan. Conversely,
cat-2 mutants seemed much less affected by Mn-induced oxidative
stress, as Mn treatment did not lead to detectable increase in ROS
and only led to a significant increase in isoprostane levels above
10 mM of Mn exposure. Moreover, high Mn exposure was able to
rescue the shorter lifespan of cat-2 mutants (Figure 5A). Mn is
naturally required for the antioxidant activities of several enzymes,
such as catalase and superoxide dismutase, which activities are
critical in the aging brain [153,154,155]. Mn also has bactericidal
and fungicidal [156] properties that are exploited in pesticides,
such as Maneb. Several hypothesis can be formulated: (1) cat-2
mutants may take up less Mn than wild-type worms, possibly
below optimal levels, (2) DA depletion in cat-2 mutants could make
them feed improperly and somehow normally toxic Mn doses
would restore the metabolic balance in those worms, (3) cat-2
worms may be prone to infections and high Mn exposure would
help the worms cope with a weak immunity. The first point could
involve DA as a regulator of feeding behavior. This aspect can be
tested by measuring Mn levels, the basal slowing response [157],
sharp angle turns [158] and the pharyngeal pumping rate of dat-1,
cat-2, cat-2;dat-1 and wild-type animals upon Mn exposure. Those
tests would also allow functional characterization of the DAergic
circuit of Mn-exposed worms. The second hypothesis involves
energy depletion as a cause of shortened lifespan, whereas the
stress of Mn exposure would restrict energy expenditure by
inhibiting the Insulin/IGF-1 pathway, possibly involving SKN-1
activation. In this case, Mn intake may not be different from other
worms. Mn level measurements, Nile red and oil red O [159]
staining to monitor fat stores, as well as RT-PCR and western-
blots to measure daf-2, akt-1/-2, sgk-1, daf-16 and skn-1 expression
levels would allow to test this idea. The third hypothesis implies
that DA-derived ROS naturally play a role in the worm’s
immunity and that a high Mn dose compensates for their absence
in cat-2 mutants. The reasoning behind this idea is detailed in the
next paragraph. This could be easily tested by comparing the
resistance to infections of wild-type, dat-1, cat-2, cat-2;dat-1 and bli-
3 mutants in presence or absence of Mn.
Mn, DA, BLI-3: a link between immunity and
neurodegeneration?
Our data show that DA and BLI-3-dependent ROS production
is triggered or amplified by Mn, which was shown to be taken up
by the NRAMP/DMT orthologues, smf-1, -2 and -3 [66].
Recently, bli-3 and BLI-3-generated ROS have been implicated
in C. elegans defense against bacteria and fungi [105,106]. The
NRAMP/DMT family of metal transporters has a well-established
role in innate immunity in vertebrates [160,161,162,163]. In C.
elegans, NRAMP/DMT orthologue deletion mutants were found to
be hypersensitive to Staphyloccocus aureus infection, which was
rescued by Mn feeding [164]. Involvement of BLI-3-generated
ROS, Mn and NRAMP/DMT in the defense against pathogens in
C. elegans, as well as in DA-dependent neurodegeneration, raises
the question of a link between immunity and DAergic neurode-
generation. The finding that DA and Mn act synergistically in a
BLI-3-dependent ROS production pathway suggests that DA may
play a direct role in the worm’s immunity. If this mechanism is
conserved in vertebrates, perhaps as a relic of a primitive immune
system, it could bear interesting implications for brain physiology.
For instance, DA-derived ROS could help fight infections when
the blood-brain barrier (BBB) is compromised. On the other hand,
they could also injure the brain and more specifically the DAT-
expressing DAergic neurons. Infections and inflammation have
long been suspected to play a role in the etiology of PD, as various
infections have been associated with cases of PD
[165,166,167,168,169,170,171,172]. The identification of a DA-
derived ROS production mechanism implicating dual oxidases
may hold some clues for the understanding of those associations.
Summary
This study confirms the conservation across the animal kingdom
of molecular pathways involved in manganism and PD, provides
the grounds for further biochemical and genetic investigations
using the C. elegans model to tackle the complex issue of
environment-gene interactions in age-related DAergic neurode-
generative disorders, and unravels the essential role of extracellular
DA oxidation and the NADPH dual-oxidase, BLI-3, upstream of
DAT-1 requirement in the neurodegeneration pathway. The data
also point to a genetic link with distinct and more general aging
processes, such as the diet-restriction pathway through the
involvement of SKN-1, and with an innate immunity genetic
network involving metal-content regulation via the SMF trans-
porters and oxidative defence mechanisms via BLI-3 in C. elegans.
Materials and Methods
C. elegans strains and handling of the worms
C. elegans strains were handled and maintained at 20uCa s
previously described [173]. The following strains were used: N2
(+); BY200, dat-1::GFP(vtIs1) V; BZ555, dat-1::GFP(egIs1); VH15,
glr-1::GFP(rhIS4) III; LX929, unc-17::GFP(vsIs48); EG1285, lin-
15B(n765) unc-47::GFP(oxIs12) X; DA1240, adIs1240[lin-15((+) eat-
4::GFP) lin-15B(n765) X; LX734, dop-2(vs105) V; dop-1(vs100) dop-
3(vs106) X; LX831, lin-15B(n765) X; DOP-1::GFP(vsIs28) dop-
3::RFP (vsIs33); RM2702, dat-1(ok157) III; MT9772, mod-5(n3314)
I; CB1111, cat-1(e1111) X; CB1112, cat-2(e1112) II; CB767, bli-
3(e767) I; BY602, cat-2(e1112) II; dat-1(ok157) III; BY645, dat-
1(ok157) III; dat-1::GFP(vtIs1) V; VC1772, skn-1(ok2315) IV;nT1[-
qIs51](IV;V). All strains were provided by the Caenorhabditis
Genetic Center (CGC, Minnesota), except for the BY602 and
BY645 strains, which were generously provided by Randy Blakely
(Vanderbilt University Medical Center, TN, USA).
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Acute (30 min) manganese chloride (MnCl2) treatments were
performed on 5,000 synchronized L1 per sample, and live worms
were scored 24 h later, as previously described [66]. Scores were
normalized to percent control (0 mM MnCl2 exposure).
Acute dopamine treatments
Dopamine (Sigma Chemical Co., St Louis, MO) solutions were
prepared in M9 buffer. Acute (30 min) treatments on young L1
worms were first tested from 1 mM to 50 mM DA, guiding us in
choosing 10 mM as the working sub-lethal dose. Synchronized L1
were acutely pre-treated with 10 mM DA for 10 min, washed 5
times in 85 mM NaCl solution and subjected to MnCl2 acute
treatments. Control worms were pre-treated with M9.
Dopamine content measurement
Synchronized L1 worms were collected, washed three times in
85 mM NaCl and distributed in tetraplicates of 200,000 L1.
Worms were pelleted and the supernatant was removed. The tubes
were then immediately frozen in liquid nitrogen and stored at
280uC. For each tube, the worm pellet was re-suspended in lysis
buffer containing EDTA to scavenge free metal ions and was
sonicated to disrupt cell membranes. Fifty mL of the lysate was
used to perform a BCA assay to measure protein levels.
Isoproterenol was added as an internal standard to the remaining
250 mL of the lysate, which was applied to the aluminum
membrane to bind DA. Collected DA samples were then
processed for High Performance Liquid Chromatography
(HPLC). To correct for inter-sample variations in the extraction
efficiency, the ratio of DA to the internal standard, isoproternol,
was estimated, and the total DA content was calculated relative
either to protein levels or to the number of worms.
Isoprostane content measurement
Worms were grown at high densities on 8P-plates. 20,000
synchronized L1 per sample were washed off the plates in 85 mM
NaCl, collected in10 mL 85 mMNaCl andacutely treated (30 min
under gentle agitation) with MnCl2. Worms were pelleted and
washed three times in 85 mM NaCl and then re-suspended in
85 mM NaCl, 0.5% Triton X-100, 5 mM Tris Buffer pH 6.8, 0.56
protease inhibitor cocktail (Sigma P8340) with zirconia beads, up to
1 mL. Samples were then processed with a Mini beadbeater-16
(Biospec Products, OK, USA) for 7 cycles of 20 s and kept 1 min in
ice-cold water after each cycle. 20 mL of supernatant per sample
were kept for measurement of protein levels by the Bradford
method. 850 mL were added to 10 mL Folch solution and gently
shaken every 5 min for 30 min. 2 mL of 0.9% NaCl per tube were
added. Tubes were centrifuged at 3,000 rpm for 10 min at 4uC, the
aqueouslayerwas discarded,andtheorganicphasewasdriedunder
nitrogen flow at 37uC. The detailed procedures for the purification
and derivatization steps were previously described [174].
ROS measurement
Synchronized L1 were acutely treated with MnCl2 as described
earlier and washed 4 additional times in M9 buffer. 2979
dichlorodihydrofluorescein diacetate (H2DCF-DA) was added at
1 mM for one hour in the dark. Worms were then washed 4 times
in M9 buffer. Worms were frozen and thawed twice and
homogenized by sonication and then centrifuged. The superna-
tants were transferred to a 96-well plate and their fluorescence
levels (excitation: 485 nm; emission: 535 nm) were detected using
a FLEXstation III (Molecular Devices, Sunnyvale, California) pre-
heated at 37uC. The fluorescence from each well was measured
every 20 min for up to 2 h. Here, we report values obtained at
1 h. Fluorescence measurements were normalized to time zero
values, and rates of increase in fluorescence (reflecting ROS levels)
were expressed as percent control. Measurements were repeated 3
times, each condition was performed in triplicate, and the
experiment was repeated in three independent worm preparations
for each tested strain.
Lifespan experiments
Synchronized L1 worms were acutely exposed to MnCl2
concentrations as described earlier. Live and healthy-looking
worms (60–66 per condition) were collected on the same day at the
late L4 stage and transferred every five days to new OP50-seeded
NGM plates. Survival was assessed every two to three days until all
worms had died. All tested C. elegans strains were assessed in
parallel, and each experiment was performed three times, yielding
qualitatively identical results. Plotted curves represent averages of
those triplicate independent experiments.
Epifluorescence, DIC, and confocal microscopy
For each slide, at least 30 worms were mounted on 4% agarose
pads in M9 and anaesthetized with 0.2% tricaine/0.02%
tetramisole in M9. Fluorescence observations and scoring of
neuronal defects were performed with an epifluorescence micro-
scope (Nikon Eclipse 80i, Nikon Corporation, Tokyo, Japan)
equipped with a Lambda LS Xenon lamp (Sutter Instrument
Company) and Nikon Plan Fluor 206 dry and Nikon Plan Apo
6061.3 oil objectives. Confocal images acquired for illustration or
GFP intensity measurement purposes were captured through Plan-
Neofluar 406, Plan-Apochromat 636, or Plan-Neofluar 1006oil
objectives with a 1.3, 1.4 and 1.3 apertures, respectively, on a
LSM510 confocal microscope (Carl Zeiss MicroImaging, Inc.)
scanning every 200 nm for XZ sections. Images were processed
with the Zeiss LSM Image Browser 4.0.0.157 software and edited
using Photoshop 7.0 (Adobe). Microscopes were housed in air-
conditioned rooms (20–22uC). Amphid and phasmid neuron
staining was performed following MnCl2 acute treatment by
soaking the worms for 2 h in a 10 mg/mL DiI solution prepared
with M9, washing off the dye for 1 h in M9 and then recovering
the worms on OP50 coated NGM plates.
SKN-1::GFP fluorescence measurements
SKN-1::GFP transgenic worms were acutely treated as
previously described, transferred to OP50-1 seeded NGM plates
and imaged 1 h post-treatment. Fluorescence measurements of the
SKN-1::GFP signal were performed on complete confocal Z-stack
maximal projections of L1 C. elegans ASI neurons. Treated and
untreated animals were mounted on the same slide and imaged
with the same magnification, gain, offset, pinhole and laser power
settings. GFP integral intensity and signal density of the maximal
projection of the ASI nuclei were measured with the freeware
ImageJ (developed by Wayne Rasband, NIMH, Maryland, USA).
Statistics
Dose-response lethality curves, longevity curves and histograms
for DA, isoprostane or ROS content measurements were
generated with GraphPad Prism (GraphPad Software Inc.). We
used a sigmoidal dose-response model with a top constraint at
100% to draw the curves and determine the LD50 or the average
lifespan values reported in the graphs. Statistical analysis of
significance was carried out by one-way ANOVA for the dose-
response curves, longevity curves and dopamine measurements;
two-way ANOVA was used to measure isoprostane and ROS
BLI-3/Dopamine-Dependent Mn-Induced Neurotoxicity
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value was less than 0.05. For SKN-1::GFP fluorescence analysis,
unpaired two-tailed T-test was used to assess statistical differences
in mean values. In all figures, error bars represent SEM; * refers to
differences between genotypes; # refers to differences between
doses; */# p,0.05; **/## p,0.01; and ***/### p,0.001.
Supporting Information
Figure S1 mod-5 loss of function does not affect Mn-induced
lethality. The serotonin re-uptake transporter (SERT) mutant mod-
5(n3314) is not significantly different from wild type (p.0.05)
regarding Mn sensitivity, and is characterized by an LD50=45 mM.
Found at: doi:10.1371/journal.pgen.1001084.s001 (0.12 MB TIF)
Figure S2 cat-2(e1112) exhibits higher ROS levels than wild type
upon Fe exposure. Both wild-type and cat-1(e1112) worms display
significantly higher ROS levels upon 1 mM FeSO4 acute
exposure (p,0.01). cat-1(e1112) mutants also show a significant
increase compared to wild-type worms (p,0.05).
Found at: doi:10.1371/journal.pgen.1001084.s002 (0.10 MB
TIF)
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